factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 12-32 | 22-32 | T10 | supported treatments | ISA | 12 | 32 | preserve | 12-21 | 12-21 | T1 | supported | TherapeuticOrPreventiveProcedure | 12 | 21 | preserve | 22-32 | 22-32 | T2 | treatments | TherapeuticOrPreventiveProcedure | 22 | 32 | A19 | Empirically supported treatments of disease-related symptoms in pediatric psychology: asthma, diabetes, and cancer. | 0-121 | 0 | 121 | Empirically @SUBJECT$ @PREDICAT$ @OBJECT$ of disease-related symptoms in pediatric psychology: asthma, diabetes, and cancer. |
Fact | preserve | 203-211 | 203-211 | T29 | reducing | PREVENTS | 203 | 211 | preserve | 178-188 | 178-188 | T14 | treatments | TherapeuticOrPreventiveProcedure | 178 | 188 | preserve | 212-229 | 221-229 | T15 | physical symptoms | SignOrSymptom | 212 | 229 | A20 | OBJECTIVE: To review empirical studies of psychological treatments for (1) reducing physical symptoms in children and adolescents with asthma, (2) improving glycemic control in children and adolescents with diabetes, and (3) reducing chemotherapy side effects in children and adolescents with cancer. | 122-440 | 122 | 440 | OBJECTIVE: To review empirical studies of psychological @SUBJECT$ for (1) @PREDICAT$ @OBJECT$ in children and adolescents with asthma, (2) improving glycemic control in children and adolescents with diabetes, and (3) reducing chemotherapy side effects in children and adolescents with cancer. |
Fact | preserve | 258-262 | 258-262 | T34 | with | PROCESS_OF | 258 | 262 | preserve | 263-269 | 263-269 | T18 | asthma | DiseaseOrSyndrome | 263 | 269 | preserve | 233-241 | 233-241 | T16 | children | AgeGroup | 233 | 241 | A21 | OBJECTIVE: To review empirical studies of psychological treatments for (1) reducing physical symptoms in children and adolescents with asthma, (2) improving glycemic control in children and adolescents with diabetes, and (3) reducing chemotherapy side effects in children and adolescents with cancer. | 122-440 | 122 | 440 | OBJECTIVE: To review empirical studies of psychological treatments for (1) reducing physical symptoms in @OBJECT$ and adolescents @PREDICAT$ @SUBJECT$ , (2) improving glycemic control in children and adolescents with diabetes, and (3) reducing chemotherapy side effects in children and adolescents with cancer. |
Fact | preserve | 974-978 | 974-978 | T92 | with | PROCESS_OF | 974 | 978 | preserve | 1001-1007 | 1001-1007 | T76 | asthma | DiseaseOrSyndrome | 1,001 | 1,007 | preserve | 965-973 | 965-973 | T74 | children | AgeGroup | 965 | 973 | A23 | RESULTS: Two well-established treatments (EMG biofeedback for children with emotionally triggered asthma and imagery with suggestion for children undergoing chemotherapy) and two probably efficacious treatments (relaxation for children with emotionally triggered asthma and distraction with relaxation for children undergoing chemotherapy) were identified. | 897-1277 | 897 | 1,277 | RESULTS: Two well-established treatments (EMG biofeedback for @OBJECT$ @PREDICAT$ emotionally triggered @SUBJECT$ and imagery with suggestion for children undergoing chemotherapy) and two probably efficacious treatments (relaxation for children with emotionally triggered asthma and distraction with relaxation for children undergoing chemotherapy) were identified. |
Uncommitted | preserve | 1326-1332 | 1326-1332 | T89 | reduce | PREVENTS | 1,326 | 1,332 | preserve | 1310-1319 | 1310-1319 | T83 | bupropion | OrganicChemical | 1,310 | 1,319 | preserve | 1337-1356 | 1348-1356 | T84 | depressive symptoms | SignOrSymptom | 1,337 | 1,356 | A1 | We considered whether a combination of venlafaxine and bupropion would reduce the depressive symptoms of a patient who was unresponsive to various classes of psychotropic agents. | 1249-1440 | 1,249 | 1,440 | We considered whether a combination of venlafaxine and @SUBJECT$ would @PREDICAT$ the @OBJECT$ of a patient who was unresponsive to various classes of psychotropic agents. |
Fact | preserve | 1200-1202 | 1200-1202 | T79 | in | PROCESS_OF | 1,200 | 1,202 | preserve | 1191-1199 | 1191-1199 | T76 | response | ClinicalAttribute | 1,191 | 1,199 | preserve | 1203-1211 | 1203-1211 | T77 | patients | PatientOrDisabledGroup | 1,203 | 1,211 | A2 | Recent data indicate that combinations of selective serotonin-reuptake inhibitors and bupropion can convert partial response to full response in patients with treatment-resistant depression. | 1045-1248 | 1,045 | 1,248 | Recent data indicate that combinations of selective serotonin-reuptake inhibitors and bupropion can convert partial response to full @SUBJECT$ @PREDICAT$ @OBJECT$ with treatment-resistant depression. |
Fact | preserve | 898-955 | 949-955 | T64 | Venlafaxine and bupropion are antidepressant agents | ISA | 898 | 955 | preserve | 898-909 | 898-909 | T57 | Venlafaxine | OrganicChemical | 898 | 909 | preserve | 934-955 | 949-955 | T59 | antidepressant agents | PharmacologicSubstance | 934 | 955 | A3 | DISCUSSION: Venlafaxine and bupropion are antidepressant agents with unique pharmacologic profiles, each effective in the treatment of depression. | 886-1044 | 886 | 1,044 | DISCUSSION: @SUBJECT$ @PREDICAT$ @OBJECT$ with unique pharmacologic profiles, each effective in the treatment of depression. |
Fact | preserve | 898-955 | 949-955 | T64 | Venlafaxine and bupropion are antidepressant agents | ISA | 898 | 955 | preserve | 914-923 | 914-923 | T58 | bupropion | OrganicChemical | 914 | 923 | preserve | 934-955 | 949-955 | T59 | antidepressant agents | PharmacologicSubstance | 934 | 955 | A4 | DISCUSSION: Venlafaxine and bupropion are antidepressant agents with unique pharmacologic profiles, each effective in the treatment of depression. | 886-1044 | 886 | 1,044 | DISCUSSION: @PREDICAT$ @SUBJECT$ are @OBJECT$ with unique pharmacologic profiles, each effective in the treatment of depression. |
Fact | preserve | 1544-1550 | 1544-1550 | T101 | reduce | PREVENTS | 1,544 | 1,550 | preserve | 1489-1498 | 1489-1498 | T93 | bupropion | OrganicChemical | 1,489 | 1,498 | preserve | 1551-1570 | 1562-1570 | T94 | depressive symptoms | SignOrSymptom | 1,551 | 1,570 | A5 | Gradual administration of venlafaxine and bupropion acted synergistically to significantly reduce depressive symptoms (p < 0.002) and significantly increase social function (p < 0.002) over a period of eight months. | 1441-1674 | 1,441 | 1,674 | Gradual administration of venlafaxine and @SUBJECT$ acted synergistically to significantly @PREDICAT$ @OBJECT$ (p < 0.002) and significantly increase social function (p < 0.002) over a period of eight months. |
Fact | preserve | 898-955 | 949-955 | T67 | Venlafaxine and bupropion are antidepressant agents | TREATS | 898 | 955 | preserve | 898-909 | 898-909 | T57 | Venlafaxine | OrganicChemical | 898 | 909 | preserve | 1033-1043 | 1033-1043 | T63 | depression | MentalOrBehavioralDysfunction | 1,033 | 1,043 | A6 | DISCUSSION: Venlafaxine and bupropion are antidepressant agents with unique pharmacologic profiles, each effective in the treatment of depression. | 886-1044 | 886 | 1,044 | DISCUSSION: @SUBJECT$ @PREDICAT$ with unique pharmacologic profiles, each effective in the treatment of @OBJECT$ . |
Fact | preserve | 191-195 | 191-195 | T15 | with | PROCESS_OF | 191 | 195 | preserve | 217-233 | 223-233 | T12 | major depression | MentalOrBehavioralDysfunction | 217 | 233 | preserve | 183-190 | 183-190 | T9 | patient | PatientOrDisabledGroup | 183 | 190 | A7 | OBJECTIVE: To report the therapeutic efficacy of venlafaxine and bupropion in a patient with treatment-refractory major depression. | 97-234 | 97 | 234 | OBJECTIVE: To report the therapeutic efficacy of venlafaxine and bupropion in a @OBJECT$ @PREDICAT$ treatment-refractory @SUBJECT$ . |
Fact | preserve | 1544-1550 | 1544-1550 | T101 | reduce | PREVENTS | 1,544 | 1,550 | preserve | 1473-1484 | 1473-1484 | T92 | venlafaxine | OrganicChemical | 1,473 | 1,484 | preserve | 1551-1570 | 1562-1570 | T94 | depressive symptoms | SignOrSymptom | 1,551 | 1,570 | A8 | Gradual administration of venlafaxine and bupropion acted synergistically to significantly reduce depressive symptoms (p < 0.002) and significantly increase social function (p < 0.002) over a period of eight months. | 1441-1674 | 1,441 | 1,674 | Gradual administration of @SUBJECT$ and bupropion acted synergistically to significantly @PREDICAT$ @OBJECT$ (p < 0.002) and significantly increase social function (p < 0.002) over a period of eight months. |
Fact | preserve | 533-545 | 533-545 | T36 | administered | USES | 533 | 545 | preserve | 521-528 | 521-528 | T33 | patient | PatientOrDisabledGroup | 521 | 528 | preserve | 546-563 | 561-563 | T34 | venlafaxine 75 mg | ClinicalDrug | 546 | 563 | A9 | The patient was administered venlafaxine 75 mg three times daily. | 511-582 | 511 | 582 | The @SUBJECT$ was @PREDICAT$ @OBJECT$ three times daily. |
Fact | preserve | 172-174 | 172-174 | T13 | in | TREATS | 172 | 174 | preserve | 146-157 | 146-157 | T7 | venlafaxine | OrganicChemical | 146 | 157 | preserve | 217-233 | 223-233 | T12 | major depression | MentalOrBehavioralDysfunction | 217 | 233 | A10 | OBJECTIVE: To report the therapeutic efficacy of venlafaxine and bupropion in a patient with treatment-refractory major depression. | 97-234 | 97 | 234 | OBJECTIVE: To report the therapeutic efficacy of @SUBJECT$ and bupropion @PREDICAT$ a patient with treatment-refractory @OBJECT$ . |
Fact | preserve | 172-174 | 172-174 | T13 | in | TREATS | 172 | 174 | preserve | 162-171 | 162-171 | T8 | bupropion | OrganicChemical | 162 | 171 | preserve | 183-190 | 183-190 | T9 | patient | PatientOrDisabledGroup | 183 | 190 | A11 | OBJECTIVE: To report the therapeutic efficacy of venlafaxine and bupropion in a patient with treatment-refractory major depression. | 97-234 | 97 | 234 | OBJECTIVE: To report the therapeutic efficacy of venlafaxine and @SUBJECT$ @PREDICAT$ a @OBJECT$ with treatment-refractory major depression. |
Fact | preserve | 1770-1774 | 1770-1774 | T114 | with | USES | 1,770 | 1,774 | preserve | 1750-1769 | 1762-1769 | T106 | combination therapy | TherapeuticOrPreventiveProcedure | 1,750 | 1,769 | preserve | 1797-1806 | 1797-1806 | T108 | bupropion | OrganicChemical | 1,797 | 1,806 | A12 | CONCLUSIONS: To our knowledge this is the first report of successful combination therapy with venlafaxine and bupropion in treatment of chronic recurrent and refractory major depression. | 1675-1880 | 1,675 | 1,880 | CONCLUSIONS: To our knowledge this is the first report of successful @SUBJECT$ @PREDICAT$ venlafaxine and @OBJECT$ in treatment of chronic recurrent and refractory major depression. |
Fact | preserve | 898-955 | 949-955 | T67 | Venlafaxine and bupropion are antidepressant agents | TREATS | 898 | 955 | preserve | 914-923 | 914-923 | T58 | bupropion | OrganicChemical | 914 | 923 | preserve | 1033-1043 | 1033-1043 | T63 | depression | MentalOrBehavioralDysfunction | 1,033 | 1,043 | A13 | DISCUSSION: Venlafaxine and bupropion are antidepressant agents with unique pharmacologic profiles, each effective in the treatment of depression. | 886-1044 | 886 | 1,044 | DISCUSSION: @PREDICAT$ @SUBJECT$ are antidepressant agents with unique pharmacologic profiles, each effective in the treatment of @OBJECT$ . |
Fact | preserve | 1212-1216 | 1212-1216 | T80 | with | PROCESS_OF | 1,212 | 1,216 | preserve | 1217-1247 | 1237-1247 | T78 | treatment-resistant depression | MentalOrBehavioralDysfunction | 1,217 | 1,247 | preserve | 1203-1211 | 1203-1211 | T77 | patients | PatientOrDisabledGroup | 1,203 | 1,211 | A14 | Recent data indicate that combinations of selective serotonin-reuptake inhibitors and bupropion can convert partial response to full response in patients with treatment-resistant depression. | 1045-1248 | 1,045 | 1,248 | Recent data indicate that combinations of selective serotonin-reuptake inhibitors and bupropion can convert partial response to full response in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 16-45 | 38-45 | T5 | bupropion combination therapy | USES | 16 | 45 | preserve | 26-45 | 38-45 | T3 | combination therapy | TherapeuticOrPreventiveProcedure | 26 | 45 | preserve | 16-25 | 16-25 | T2 | bupropion | OrganicChemical | 16 | 25 | A15 | Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. | 0-96 | 0 | 96 | Venlafaxine and @OBJECT$ @PREDICAT$ @SUBJECT$ in a case of treatment-resistant depression. |
Fact | preserve | 172-174 | 172-174 | T13 | in | TREATS | 172 | 174 | preserve | 146-157 | 146-157 | T7 | venlafaxine | OrganicChemical | 146 | 157 | preserve | 183-190 | 183-190 | T9 | patient | PatientOrDisabledGroup | 183 | 190 | A16 | OBJECTIVE: To report the therapeutic efficacy of venlafaxine and bupropion in a patient with treatment-refractory major depression. | 97-234 | 97 | 234 | OBJECTIVE: To report the therapeutic efficacy of @SUBJECT$ and bupropion @PREDICAT$ a @OBJECT$ with treatment-refractory major depression. |
Fact | preserve | 1020-1029 | 1020-1029 | T66 | treatment | TREATS | 1,020 | 1,029 | preserve | 934-955 | 949-955 | T59 | antidepressant agents | PharmacologicSubstance | 934 | 955 | preserve | 1033-1043 | 1033-1043 | T63 | depression | MentalOrBehavioralDysfunction | 1,033 | 1,043 | A17 | DISCUSSION: Venlafaxine and bupropion are antidepressant agents with unique pharmacologic profiles, each effective in the treatment of depression. | 886-1044 | 886 | 1,044 | DISCUSSION: Venlafaxine and bupropion are @SUBJECT$ with unique pharmacologic profiles, each effective in the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 172-174 | 172-174 | T13 | in | TREATS | 172 | 174 | preserve | 162-171 | 162-171 | T8 | bupropion | OrganicChemical | 162 | 171 | preserve | 217-233 | 223-233 | T12 | major depression | MentalOrBehavioralDysfunction | 217 | 233 | A18 | OBJECTIVE: To report the therapeutic efficacy of venlafaxine and bupropion in a patient with treatment-refractory major depression. | 97-234 | 97 | 234 | OBJECTIVE: To report the therapeutic efficacy of venlafaxine and @SUBJECT$ @PREDICAT$ a patient with treatment-refractory @OBJECT$ . |
Fact | preserve | 1770-1774 | 1770-1774 | T114 | with | USES | 1,770 | 1,774 | preserve | 1750-1769 | 1762-1769 | T106 | combination therapy | TherapeuticOrPreventiveProcedure | 1,750 | 1,769 | preserve | 1781-1792 | 1781-1792 | T107 | venlafaxine | OrganicChemical | 1,781 | 1,792 | A19 | CONCLUSIONS: To our knowledge this is the first report of successful combination therapy with venlafaxine and bupropion in treatment of chronic recurrent and refractory major depression. | 1675-1880 | 1,675 | 1,880 | CONCLUSIONS: To our knowledge this is the first report of successful @SUBJECT$ @PREDICAT$ @OBJECT$ and bupropion in treatment of chronic recurrent and refractory major depression. |
Uncommitted | preserve | 1326-1332 | 1326-1332 | T89 | reduce | PREVENTS | 1,326 | 1,332 | preserve | 1294-1305 | 1294-1305 | T82 | venlafaxine | OrganicChemical | 1,294 | 1,305 | preserve | 1337-1356 | 1348-1356 | T84 | depressive symptoms | SignOrSymptom | 1,337 | 1,356 | A20 | We considered whether a combination of venlafaxine and bupropion would reduce the depressive symptoms of a patient who was unresponsive to various classes of psychotropic agents. | 1249-1440 | 1,249 | 1,440 | We considered whether a combination of @SUBJECT$ and bupropion would @PREDICAT$ the @OBJECT$ of a patient who was unresponsive to various classes of psychotropic agents. |
Probable | preserve | 2044-2047 | 2044-2047 | T104 | for | TREATS | 2,044 | 2,047 | preserve | 2010-2019 | 2010-2019 | T99 | therapies | TherapeuticOrPreventiveProcedure | 2,010 | 2,019 | preserve | 2054-2062 | 2054-2062 | T101 | patients | PatientOrDisabledGroup | 2,054 | 2,062 | A1 | The auricular pressing and cupping therapies may also be added for adult patients to strengthen the curative effect. | 1975-2097 | 1,975 | 2,097 | The auricular pressing and cupping @SUBJECT$ may also be added @PREDICAT$ adult @OBJECT$ to strengthen the curative effect. |
Fact | preserve | 1376-1397 | 1388-1397 | T77 | acupuncture treatment | ISA | 1,376 | 1,397 | preserve | 1376-1387 | 1376-1387 | T74 | acupuncture | TherapeuticOrPreventiveProcedure | 1,376 | 1,387 | preserve | 1388-1397 | 1388-1397 | T75 | treatment | TherapeuticOrPreventiveProcedure | 1,388 | 1,397 | A2 | There were another two children patients aged 5 and 7 years respectively, for them the above method of acupuncture treatment was difficult to be used. | 1261-1423 | 1,261 | 1,423 | There were another two children patients aged 5 and 7 years respectively, for them the above method of @SUBJECT$ @PREDICAT$ @OBJECT$ was difficult to be used. |
Fact | preserve | 1026-1040 | 1033-1040 | T57 | female patient | PROCESS_OF | 1,026 | 1,040 | preserve | 1026-1032 | 1026-1032 | T52 | female | OrganismAttribute | 1,026 | 1,032 | preserve | 1033-1040 | 1033-1040 | T53 | patient | PatientOrDisabledGroup | 1,033 | 1,040 | A3 | It is worthy to be mentioned that, in this series, there was a female patient who suffered from anaphylactic asthma induced by dog's hair. | 957-1101 | 957 | 1,101 | It is worthy to be mentioned that, in this series, there was a @SUBJECT$ @PREDICAT$ @OBJECT$ who suffered from anaphylactic asthma induced by dog's hair. |
Fact | preserve | 1045-1053 | 1045-1053 | T58 | suffered | PROCESS_OF | 1,045 | 1,053 | preserve | 1072-1078 | 1072-1078 | T55 | asthma | DiseaseOrSyndrome | 1,072 | 1,078 | preserve | 1033-1040 | 1033-1040 | T53 | patient | PatientOrDisabledGroup | 1,033 | 1,040 | A4 | It is worthy to be mentioned that, in this series, there was a female patient who suffered from anaphylactic asthma induced by dog's hair. | 957-1101 | 957 | 1,101 | It is worthy to be mentioned that, in this series, there was a female @OBJECT$ who @PREDICAT$ from anaphylactic @SUBJECT$ induced by dog's hair. |
Fact | preserve | 705-722 | 715-722 | T41 | asthmatic patient | PROCESS_OF | 705 | 722 | preserve | 705-714 | 705-714 | T34 | asthmatic | DiseaseOrSyndrome | 705 | 714 | preserve | 715-722 | 715-722 | T35 | patient | PatientOrDisabledGroup | 715 | 722 | A5 | Thus, each asthmatic patient needs to receive approximately 30 sessions of acupuncture treatment, lasting about 3 months. | 694-821 | 694 | 821 | Thus, each @SUBJECT$ @PREDICAT$ @OBJECT$ needs to receive approximately 30 sessions of acupuncture treatment, lasting about 3 months. |
Fact | preserve | 1136-1157 | 1148-1157 | T62 | acupuncture treatment | ISA | 1,136 | 1,157 | preserve | 1136-1147 | 1136-1147 | T60 | acupuncture | TherapeuticOrPreventiveProcedure | 1,136 | 1,147 | preserve | 1148-1157 | 1148-1157 | T61 | treatment | TherapeuticOrPreventiveProcedure | 1,148 | 1,157 | A6 | She received 10 sessions of acupuncture treatment with no any improvement. | 1102-1182 | 1,102 | 1,182 | She received 10 sessions of @SUBJECT$ @PREDICAT$ @OBJECT$ with no any improvement. |
Fact | preserve | 942-955 | 949-955 | T50 | summer season | ISA | 942 | 955 | preserve | 942-948 | 942-948 | T48 | summer | TemporalConcept | 942 | 948 | preserve | 949-955 | 949-955 | T49 | season | TemporalConcept | 949 | 955 | A7 | Thereafter, in order to prevent its relapse, the treatment should be administered 10 times each year in the summer season. | 822-956 | 822 | 956 | Thereafter, in order to prevent its relapse, the treatment should be administered 10 times each year in the @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Uncommitted | preserve | 775-796 | 787-796 | T43 | acupuncture treatment | ADMINISTERED_TO | 775 | 796 | preserve | 775-786 | 775-786 | T37 | acupuncture | TherapeuticOrPreventiveProcedure | 775 | 786 | preserve | 715-722 | 715-722 | T35 | patient | PatientOrDisabledGroup | 715 | 722 | A8 | Thus, each asthmatic patient needs to receive approximately 30 sessions of acupuncture treatment, lasting about 3 months. | 694-821 | 694 | 821 | Thus, each asthmatic @OBJECT$ needs to receive approximately 30 sessions of @SUBJECT$ @PREDICAT$ , lasting about 3 months. |
Fact | preserve | 228-250 | 240-250 | T17 | acupuncture treatments | ISA | 228 | 250 | preserve | 228-239 | 228-239 | T12 | acupuncture | TherapeuticOrPreventiveProcedure | 228 | 239 | preserve | 240-250 | 240-250 | T13 | treatments | TherapeuticOrPreventiveProcedure | 240 | 250 | A9 | The clinical observation revealed that the asthmatic symptoms in most of the patients began to be improved after several acupuncture treatments with the dosage of the drug gradually reduced. | 101-303 | 101 | 303 | The clinical observation revealed that the asthmatic symptoms in most of the patients began to be improved after several @SUBJECT$ @PREDICAT$ @OBJECT$ with the dosage of the drug gradually reduced. |
Fact | preserve | 1207-1228 | 1219-1228 | T67 | acupuncture treatment | ISA | 1,207 | 1,228 | preserve | 1207-1218 | 1207-1218 | T63 | acupuncture | TherapeuticOrPreventiveProcedure | 1,207 | 1,218 | preserve | 1219-1228 | 1219-1228 | T64 | treatment | TherapeuticOrPreventiveProcedure | 1,219 | 1,228 | A10 | In this case, the acupuncture treatment should not be given any longer. | 1183-1260 | 1,183 | 1,260 | In this case, the @SUBJECT$ @PREDICAT$ @OBJECT$ should not be given any longer. |
Fact | preserve | 2002-2019 | 2010-2019 | T103 | cupping therapies | ISA | 2,002 | 2,019 | preserve | 2002-2009 | 2002-2009 | T98 | cupping | TherapeuticOrPreventiveProcedure | 2,002 | 2,009 | preserve | 2010-2019 | 2010-2019 | T99 | therapies | TherapeuticOrPreventiveProcedure | 2,010 | 2,019 | A12 | The auricular pressing and cupping therapies may also be added for adult patients to strengthen the curative effect. | 1975-2097 | 1,975 | 2,097 | The auricular pressing and @SUBJECT$ @PREDICAT$ @OBJECT$ may also be added for adult patients to strengthen the curative effect. |
Fact | preserve | 775-796 | 787-796 | T40 | acupuncture treatment | ISA | 775 | 796 | preserve | 775-786 | 775-786 | T37 | acupuncture | TherapeuticOrPreventiveProcedure | 775 | 786 | preserve | 787-796 | 787-796 | T38 | treatment | TherapeuticOrPreventiveProcedure | 787 | 796 | A13 | Thus, each asthmatic patient needs to receive approximately 30 sessions of acupuncture treatment, lasting about 3 months. | 694-821 | 694 | 821 | Thus, each asthmatic patient needs to receive approximately 30 sessions of @SUBJECT$ @PREDICAT$ @OBJECT$ , lasting about 3 months. |
Fact | preserve | 1079-1086 | 1079-1086 | T59 | induced | CAUSES | 1,079 | 1,086 | preserve | 1090-1100 | 1096-1100 | T56 | dog's hair | BodySubstance | 1,090 | 1,100 | preserve | 1072-1078 | 1072-1078 | T55 | asthma | DiseaseOrSyndrome | 1,072 | 1,078 | A14 | It is worthy to be mentioned that, in this series, there was a female patient who suffered from anaphylactic asthma induced by dog's hair. | 957-1101 | 957 | 1,101 | It is worthy to be mentioned that, in this series, there was a female patient who suffered from anaphylactic @OBJECT$ @PREDICAT$ by @SUBJECT$ . |
Uncommitted | preserve | 732-739 | 732-739 | T42 | receive | ADMINISTERED_TO | 732 | 739 | preserve | 787-796 | 787-796 | T38 | treatment | TherapeuticOrPreventiveProcedure | 787 | 796 | preserve | 715-722 | 715-722 | T35 | patient | PatientOrDisabledGroup | 715 | 722 | A15 | Thus, each asthmatic patient needs to receive approximately 30 sessions of acupuncture treatment, lasting about 3 months. | 694-821 | 694 | 821 | Thus, each asthmatic @OBJECT$ needs to @PREDICAT$ approximately 30 sessions of acupuncture @SUBJECT$ , lasting about 3 months. |
Probable | preserve | 2002-2019 | 2010-2019 | T105 | cupping therapies | TREATS | 2,002 | 2,019 | preserve | 2002-2009 | 2002-2009 | T98 | cupping | TherapeuticOrPreventiveProcedure | 2,002 | 2,009 | preserve | 2054-2062 | 2054-2062 | T101 | patients | PatientOrDisabledGroup | 2,054 | 2,062 | A16 | The auricular pressing and cupping therapies may also be added for adult patients to strengthen the curative effect. | 1975-2097 | 1,975 | 2,097 | The auricular pressing and @SUBJECT$ @PREDICAT$ may also be added for adult @OBJECT$ to strengthen the curative effect. |
Fact | preserve | 339-354 | 346-354 | T29 | stroke patients | PROCESS_OF | 339 | 354 | preserve | 339-345 | 339-345 | T23 | stroke | DiseaseOrSyndrome | 339 | 345 | preserve | 346-354 | 346-354 | T24 | patients | PatientOrDisabledGroup | 346 | 354 | A1 | Improving compliance to antihypertensive therapy in African-American stroke patients could have a significant impact on recurrent stroke rates. | 264-419 | 264 | 419 | Improving compliance to antihypertensive therapy in African-American @SUBJECT$ @PREDICAT$ @OBJECT$ could have a significant impact on recurrent stroke rates. |
Possible | preserve | 319-321 | 319-321 | T30 | in | TREATS | 319 | 321 | preserve | 294-318 | 311-318 | T21 | antihypertensive therapy | TherapeuticOrPreventiveProcedure | 294 | 318 | preserve | 339-345 | 339-345 | T23 | stroke | DiseaseOrSyndrome | 339 | 345 | A3 | Improving compliance to antihypertensive therapy in African-American stroke patients could have a significant impact on recurrent stroke rates. | 264-419 | 264 | 419 | Improving compliance to @SUBJECT$ @PREDICAT$ African-American @OBJECT$ patients could have a significant impact on recurrent stroke rates. |
Fact | preserve | 149-154 | 149-154 | T18 | cause | CAUSES | 149 | 154 | preserve | 125-137 | 125-137 | T8 | Hypertension | DiseaseOrSyndrome | 125 | 137 | preserve | 158-164 | 158-164 | T11 | stroke | DiseaseOrSyndrome | 158 | 164 | A4 | Hypertension is a major cause of stroke in the African-American community, and lack of control of hypertension appears to be common. | 125-263 | 125 | 263 | @SUBJECT$ is a major @PREDICAT$ of @OBJECT$ in the African-American community, and lack of control of hypertension appears to be common. |
Fact | preserve | 59-74 | 66-74 | T7 | stroke patients | PROCESS_OF | 59 | 74 | preserve | 59-65 | 59-65 | T3 | stroke | DiseaseOrSyndrome | 59 | 65 | preserve | 66-74 | 66-74 | T4 | patients | PatientOrDisabledGroup | 66 | 74 | A5 | Antihypertensive medication compliance in African-American stroke patients: behavioral epidemiology and interventions. | 0-124 | 0 | 124 | Antihypertensive medication compliance in African-American @SUBJECT$ @PREDICAT$ @OBJECT$ : behavioral epidemiology and interventions. |
Fact | preserve | 319-321 | 319-321 | T30 | in | TREATS | 319 | 321 | preserve | 294-318 | 311-318 | T21 | antihypertensive therapy | TherapeuticOrPreventiveProcedure | 294 | 318 | preserve | 346-354 | 346-354 | T24 | patients | PatientOrDisabledGroup | 346 | 354 | A7 | Improving compliance to antihypertensive therapy in African-American stroke patients could have a significant impact on recurrent stroke rates. | 264-419 | 264 | 419 | Improving compliance to @SUBJECT$ @PREDICAT$ African-American stroke @OBJECT$ could have a significant impact on recurrent stroke rates. |
Fact | preserve | 1612-1619 | 1612-1619 | T86 | prevent | PREVENTS | 1,612 | 1,619 | preserve | 1591-1607 | 1599-1607 | T84 | Regular exercise | DailyOrRecreationalActivity | 1,591 | 1,607 | preserve | 1620-1632 | 1620-1632 | T85 | hypertension | DiseaseOrSyndrome | 1,620 | 1,632 | A1 | Regular exercise can prevent hypertension. | 1591-1633 | 1,591 | 1,633 | @SUBJECT$ can @PREDICAT$ @OBJECT$ . |
Uncommitted | preserve | 319-323 | 319-323 | T19 | risk | PREDISPOSES | 319 | 323 | preserve | 262-266 | 262-266 | T14 | walk | Finding | 262 | 266 | preserve | 334-346 | 334-346 | T18 | hypertension | DiseaseOrSyndrome | 334 | 346 | A2 | OBJECTIVE: To investigate the association of the duration of the walk to work and leisure-time physical activity with the risk for hypertension. | 191-347 | 191 | 347 | OBJECTIVE: To investigate the association of the duration of the @SUBJECT$ to work and leisure-time physical activity with the @PREDICAT$ for @OBJECT$ . |
Fact | preserve | 1574-1576 | 1574-1576 | T83 | in | PROCESS_OF | 1,574 | 1,576 | preserve | 1561-1573 | 1561-1573 | T80 | hypertension | DiseaseOrSyndrome | 1,561 | 1,573 | preserve | 1586-1589 | 1586-1589 | T81 | men | PopulationGroup | 1,586 | 1,589 | A3 | CONCLUSIONS: Walking to work and other types of physical activity decreased the risk for hypertension in Japanese men. | 1466-1590 | 1,466 | 1,590 | CONCLUSIONS: Walking to work and other types of physical activity decreased the risk for @SUBJECT$ @PREDICAT$ Japanese @OBJECT$ . |
Fact | preserve | 46-48 | 46-48 | T5 | in | PROCESS_OF | 46 | 48 | preserve | 33-45 | 33-45 | T2 | hypertension | DiseaseOrSyndrome | 33 | 45 | preserve | 49-52 | 49-52 | T3 | men | PopulationGroup | 49 | 52 | A6 | Walking to work and the risk for hypertension in men: the Osaka Health Survey. | 0-78 | 0 | 78 | Walking to work and the risk for @SUBJECT$ @PREDICAT$ @OBJECT$ : the Osaka Health Survey. |
Uncommitted | preserve | 319-323 | 319-323 | T19 | risk | PREDISPOSES | 319 | 323 | preserve | 279-309 | 301-309 | T16 | leisure-time physical activity | DailyOrRecreationalActivity | 279 | 309 | preserve | 334-346 | 334-346 | T18 | hypertension | DiseaseOrSyndrome | 334 | 346 | A7 | OBJECTIVE: To investigate the association of the duration of the walk to work and leisure-time physical activity with the risk for hypertension. | 191-347 | 191 | 347 | OBJECTIVE: To investigate the association of the duration of the walk to work and @SUBJECT$ with the @PREDICAT$ for @OBJECT$ . |
Fact | preserve | 406-416 | 406-416 | T44 | metabolize | INTERACTS_WITH | 406 | 416 | preserve | 402-405 | 402-405 | T30 | ACE | AminoAcidPeptideOrProtein | 402 | 405 | preserve | 439-449 | 439-449 | T32 | bradykinin | AminoAcidPeptideOrProtein | 439 | 449 | A3 | Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. | 383-617 | 383 | 617 | Given that NEP and @SUBJECT$ @PREDICAT$ angiotensin (Ang) and @OBJECT$ (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. |
Fact | preserve | 590-594 | 590-594 | T54 | with | PROCESS_OF | 590 | 594 | preserve | 595-616 | 606-616 | T43 | myocardial infarction | DiseaseOrSyndrome | 595 | 616 | preserve | 585-589 | 585-589 | T42 | rats | Mammal | 585 | 589 | A4 | Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. | 383-617 | 383 | 617 | Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Counterfact | preserve | 1039-1046 | 1039-1046 | T95 | reduced | PREVENTS | 1,039 | 1,046 | preserve | 1007-1018 | 1007-1018 | T84 | perindopril | OrganicChemical | 1,007 | 1,018 | preserve | 1047-1066 | 1055-1066 | T86 | cardiac hypertrophy | PathologicFunction | 1,047 | 1,066 | A7 | Neither perindopril nor ecadotril reduced cardiac hypertrophy when administered separately, whereas the combination of perindopril and 10 or 100 mg/kg/day ecadotril reduced heart weight/body weight ratio by 10%. | 999-1228 | 999 | 1,228 | Neither @SUBJECT$ nor ecadotril @PREDICAT$ @OBJECT$ when administered separately, whereas the combination of perindopril and 10 or 100 mg/kg/day ecadotril reduced heart weight/body weight ratio by 10%. |
Fact | preserve | 406-416 | 406-416 | T44 | metabolize | INTERACTS_WITH | 406 | 416 | preserve | 402-405 | 402-405 | T30 | ACE | AminoAcidPeptideOrProtein | 402 | 405 | preserve | 417-428 | 417-428 | T31 | angiotensin | AminoAcidPeptideOrProtein | 417 | 428 | A10 | Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. | 383-617 | 383 | 617 | Given that NEP and @SUBJECT$ @PREDICAT$ @OBJECT$ (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. |
Fact | preserve | 265-338 | 331-338 | T21 | NEP) and angiotensin converting enzyme (ACE) is a candidate therapy | ISA | 265 | 338 | preserve | 274-309 | 303-309 | T17 | angiotensin converting enzyme | AminoAcidPeptideOrProtein | 274 | 309 | preserve | 331-338 | 331-338 | T18 | therapy | TherapeuticOrPreventiveProcedure | 331 | 338 | A11 | Combined inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) is a candidate therapy for hypertension and cardiac failure. | 213-382 | 213 | 382 | Combined inhibition of neutral endopeptidase 24.11 ( @PREDICAT$ @SUBJECT$ (ACE) is a candidate @OBJECT$ for hypertension and cardiac failure. |
Possible | preserve | 1667-1676 | 1667-1676 | T142 | reduction | DISRUPTS | 1,667 | 1,676 | preserve | 1623-1625 | 1623-1625 | T127 | BK | AminoAcidPeptideOrProtein | 1,623 | 1,625 | preserve | 1680-1699 | 1688-1699 | T129 | cardiac hypertrophy | PathologicFunction | 1,680 | 1,699 | A14 | Whereas increased cardiac BK-(1-9) levels may contribute to the reduction of cardiac hypertrophy, the reduction in plasma Ang-(1-7) levels and increase in Ang II levels in plasma and tissues may compromise the therapeutic effects of combined NEP/ACE inhibition. | 1597-1876 | 1,597 | 1,876 | Whereas increased cardiac @SUBJECT$ -(1-9) levels may contribute to the @PREDICAT$ of @OBJECT$ , the reduction in plasma Ang-(1-7) levels and increase in Ang II levels in plasma and tissues may compromise the therapeutic effects of combined NEP/ACE inhibition. |
Fact | preserve | 1229-1243 | 1229-1243 | T112 | Administration | ADMINISTERED_TO | 1,229 | 1,243 | preserve | 1247-1256 | 1247-1256 | T97 | ecadotril | AminoAcidPeptideOrProtein | 1,247 | 1,256 | preserve | 1280-1284 | 1280-1284 | T100 | rats | Mammal | 1,280 | 1,284 | A15 | Administration of ecadotril to perindopril-treated rats decreased plasma Ang-(1-7) levels, increased cardiac BK-(1-9) levels, and increased Ang II levels in plasma, kidney, aorta, and lung. | 1229-1431 | 1,229 | 1,431 | @PREDICAT$ of @SUBJECT$ to perindopril-treated @OBJECT$ decreased plasma Ang-(1-7) levels, increased cardiac BK-(1-9) levels, and increased Ang II levels in plasma, kidney, aorta, and lung. |
Probable | preserve | 339-342 | 339-342 | T23 | for | TREATS | 339 | 342 | preserve | 331-338 | 331-338 | T18 | therapy | TherapeuticOrPreventiveProcedure | 331 | 338 | preserve | 360-381 | 374-381 | T20 | cardiac failure | DiseaseOrSyndrome | 360 | 381 | A17 | Combined inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) is a candidate therapy for hypertension and cardiac failure. | 213-382 | 213 | 382 | Combined inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) is a candidate @SUBJECT$ @PREDICAT$ hypertension and @OBJECT$ . |
Fact | preserve | 942-948 | 942-948 | T83 | effect | AFFECTS | 942 | 948 | preserve | 958-967 | 958-967 | T79 | ecadotril | AminoAcidPeptideOrProtein | 958 | 967 | preserve | 988-997 | 988-997 | T82 | excretion | PhysiologicFunction | 988 | 997 | A18 | Perindopril potentiated the effect of ecadotril on urine cyclic GMP excretion. | 914-998 | 914 | 998 | Perindopril potentiated the @PREDICAT$ of @SUBJECT$ on urine cyclic GMP @OBJECT$ . |
Fact | preserve | 101-105 | 101-105 | T13 | with | PROCESS_OF | 101 | 105 | preserve | 106-127 | 117-127 | T5 | myocardial infarction | DiseaseOrSyndrome | 106 | 127 | preserve | 96-100 | 96-100 | T4 | rats | Mammal | 96 | 100 | A19 | Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. | 0-212 | 0 | 212 | Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in @OBJECT$ @PREDICAT$ @SUBJECT$ : effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. |
Counterfact | preserve | 1039-1046 | 1039-1046 | T95 | reduced | PREVENTS | 1,039 | 1,046 | preserve | 1023-1032 | 1023-1032 | T85 | ecadotril | AminoAcidPeptideOrProtein | 1,023 | 1,032 | preserve | 1047-1066 | 1055-1066 | T86 | cardiac hypertrophy | PathologicFunction | 1,047 | 1,066 | A20 | Neither perindopril nor ecadotril reduced cardiac hypertrophy when administered separately, whereas the combination of perindopril and 10 or 100 mg/kg/day ecadotril reduced heart weight/body weight ratio by 10%. | 999-1228 | 999 | 1,228 | Neither perindopril nor @SUBJECT$ @PREDICAT$ @OBJECT$ when administered separately, whereas the combination of perindopril and 10 or 100 mg/kg/day ecadotril reduced heart weight/body weight ratio by 10%. |
Fact | preserve | 1778-1780 | 1778-1780 | T145 | in | LOCATION_OF | 1,778 | 1,780 | preserve | 1781-1787 | 1781-1787 | T136 | plasma | BodySubstance | 1,781 | 1,787 | preserve | 1764-1770 | 1768-1770 | T134 | Ang II | AminoAcidPeptideOrProtein | 1,764 | 1,770 | A22 | Whereas increased cardiac BK-(1-9) levels may contribute to the reduction of cardiac hypertrophy, the reduction in plasma Ang-(1-7) levels and increase in Ang II levels in plasma and tissues may compromise the therapeutic effects of combined NEP/ACE inhibition. | 1597-1876 | 1,597 | 1,876 | Whereas increased cardiac BK-(1-9) levels may contribute to the reduction of cardiac hypertrophy, the reduction in plasma Ang-(1-7) levels and increase in @OBJECT$ levels @PREDICAT$ @SUBJECT$ and tissues may compromise the therapeutic effects of combined NEP/ACE inhibition. |
Fact | preserve | 1778-1780 | 1778-1780 | T145 | in | LOCATION_OF | 1,778 | 1,780 | preserve | 1792-1799 | 1792-1799 | T137 | tissues | Tissue | 1,792 | 1,799 | preserve | 1764-1770 | 1768-1770 | T134 | Ang II | AminoAcidPeptideOrProtein | 1,764 | 1,770 | A24 | Whereas increased cardiac BK-(1-9) levels may contribute to the reduction of cardiac hypertrophy, the reduction in plasma Ang-(1-7) levels and increase in Ang II levels in plasma and tissues may compromise the therapeutic effects of combined NEP/ACE inhibition. | 1597-1876 | 1,597 | 1,876 | Whereas increased cardiac BK-(1-9) levels may contribute to the reduction of cardiac hypertrophy, the reduction in plasma Ang-(1-7) levels and increase in @OBJECT$ levels @PREDICAT$ plasma and @SUBJECT$ may compromise the therapeutic effects of combined NEP/ACE inhibition. |
Fact | preserve | 406-416 | 406-416 | T44 | metabolize | INTERACTS_WITH | 406 | 416 | preserve | 394-397 | 394-397 | T29 | NEP | AminoAcidPeptideOrProtein | 394 | 397 | preserve | 417-428 | 417-428 | T31 | angiotensin | AminoAcidPeptideOrProtein | 417 | 428 | A26 | Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. | 383-617 | 383 | 617 | Given that @SUBJECT$ and ACE @PREDICAT$ @OBJECT$ (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. |
Fact | preserve | 857-866 | 857-866 | T75 | increased | STIMULATES | 857 | 866 | preserve | 847-856 | 847-856 | T70 | Ecadotril | AminoAcidPeptideOrProtein | 847 | 856 | preserve | 894-896 | 894-896 | T73 | BK | AminoAcidPeptideOrProtein | 894 | 896 | A28 | Ecadotril increased urine cyclic GMP and BK-(1-9) excretion. | 847-913 | 847 | 913 | @SUBJECT$ @PREDICAT$ urine cyclic GMP and @OBJECT$ -(1-9) excretion. |
Fact | preserve | 265-338 | 331-338 | T21 | NEP) and angiotensin converting enzyme (ACE) is a candidate therapy | ISA | 265 | 338 | preserve | 265-268 | 265-268 | T16 | NEP | AminoAcidPeptideOrProtein | 265 | 268 | preserve | 331-338 | 331-338 | T18 | therapy | TherapeuticOrPreventiveProcedure | 331 | 338 | A30 | Combined inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) is a candidate therapy for hypertension and cardiac failure. | 213-382 | 213 | 382 | Combined inhibition of neutral endopeptidase 24.11 ( @SUBJECT$ @PREDICAT$ @OBJECT$ for hypertension and cardiac failure. |
Fact | preserve | 744-769 | 758-769 | T69 | ACE inhibitor perindopril | ISA | 744 | 769 | preserve | 758-769 | 758-769 | T63 | perindopril | OrganicChemical | 758 | 769 | preserve | 744-757 | 748-757 | T62 | ACE inhibitor | PharmacologicSubstance | 744 | 757 | A31 | We administered the NEP inhibitor ecadotril (0, 0.1, 1, 10, and 100 mg/kg/day), either alone or together with the ACE inhibitor perindopril (0.2 mg/kg/day) by 12-hourly gavage from day 2 to 28 after infarction. | 618-846 | 618 | 846 | We administered the NEP inhibitor ecadotril (0, 0.1, 1, 10, and 100 mg/kg/day), either alone or together with the @OBJECT$ @PREDICAT$ @SUBJECT$ (0.2 mg/kg/day) by 12-hourly gavage from day 2 to 28 after infarction. |
Fact | preserve | 857-866 | 857-866 | T75 | increased | STIMULATES | 857 | 866 | preserve | 847-856 | 847-856 | T70 | Ecadotril | AminoAcidPeptideOrProtein | 847 | 856 | preserve | 879-889 | 886-889 | T72 | cyclic GMP | BiologicallyActiveSubstance | 879 | 889 | A32 | Ecadotril increased urine cyclic GMP and BK-(1-9) excretion. | 847-913 | 847 | 913 | @SUBJECT$ @PREDICAT$ urine @OBJECT$ and BK-(1-9) excretion. |
Fact | preserve | 1301-1311 | 1308-1311 | T113 | plasma Ang | LOCATION_OF | 1,301 | 1,311 | preserve | 1301-1307 | 1301-1307 | T101 | plasma | BodySubstance | 1,301 | 1,307 | preserve | 1308-1311 | 1308-1311 | T102 | Ang | AminoAcidPeptideOrProtein | 1,308 | 1,311 | A34 | Administration of ecadotril to perindopril-treated rats decreased plasma Ang-(1-7) levels, increased cardiac BK-(1-9) levels, and increased Ang II levels in plasma, kidney, aorta, and lung. | 1229-1431 | 1,229 | 1,431 | Administration of ecadotril to perindopril-treated rats decreased @SUBJECT$ @PREDICAT$ @OBJECT$ -(1-7) levels, increased cardiac BK-(1-9) levels, and increased Ang II levels in plasma, kidney, aorta, and lung. |
Probable | preserve | 339-342 | 339-342 | T23 | for | TREATS | 339 | 342 | preserve | 331-338 | 331-338 | T18 | therapy | TherapeuticOrPreventiveProcedure | 331 | 338 | preserve | 343-355 | 343-355 | T19 | hypertension | DiseaseOrSyndrome | 343 | 355 | A35 | Combined inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) is a candidate therapy for hypertension and cardiac failure. | 213-382 | 213 | 382 | Combined inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) is a candidate @SUBJECT$ @PREDICAT$ @OBJECT$ and cardiac failure. |
Fact | preserve | 406-416 | 406-416 | T44 | metabolize | INTERACTS_WITH | 406 | 416 | preserve | 394-397 | 394-397 | T29 | NEP | AminoAcidPeptideOrProtein | 394 | 397 | preserve | 439-449 | 439-449 | T32 | bradykinin | AminoAcidPeptideOrProtein | 439 | 449 | A37 | Given that NEP and ACE metabolize angiotensin (Ang) and bradykinin (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. | 383-617 | 383 | 617 | Given that @SUBJECT$ and ACE @PREDICAT$ angiotensin (Ang) and @OBJECT$ (BK) peptides, we investigated the effects of NEP inhibition and combined NEP and ACE inhibition on Ang and BK levels in rats with myocardial infarction. |
Fact | preserve | 1718-1734 | 1731-1734 | T143 | plasma Ang | LOCATION_OF | 1,718 | 1,734 | preserve | 1718-1724 | 1718-1724 | T130 | plasma | BodySubstance | 1,718 | 1,724 | preserve | 1731-1734 | 1731-1734 | T131 | Ang | AminoAcidPeptideOrProtein | 1,731 | 1,734 | A38 | Whereas increased cardiac BK-(1-9) levels may contribute to the reduction of cardiac hypertrophy, the reduction in plasma Ang-(1-7) levels and increase in Ang II levels in plasma and tissues may compromise the therapeutic effects of combined NEP/ACE inhibition. | 1597-1876 | 1,597 | 1,876 | Whereas increased cardiac BK-(1-9) levels may contribute to the reduction of cardiac hypertrophy, the reduction in @SUBJECT$ @PREDICAT$ @OBJECT$ -(1-7) levels and increase in Ang II levels in plasma and tissues may compromise the therapeutic effects of combined NEP/ACE inhibition. |
Fact | preserve | 895-902 | 895-902 | T48 | control | TREATS | 895 | 902 | preserve | 800-810 | 800-810 | T38 | formoterol | OrganicChemical | 800 | 810 | preserve | 888-894 | 888-894 | T42 | asthma | DiseaseOrSyndrome | 888 | 894 | A4 | Despite these effects, the short-acting beta-agonist drugs albuterol and terbutaline and the long-acting beta-agonist drugs salmeterol and formoterol have, in general, not been associated with a significant worsening of asthma control or an increased frequency of severe attacks. | 648-947 | 648 | 947 | Despite these effects, the short-acting beta-agonist drugs albuterol and terbutaline and the long-acting beta-agonist drugs salmeterol and @SUBJECT$ have, in general, not been associated with a significant worsening of @OBJECT$ @PREDICAT$ or an increased frequency of severe attacks. |
Fact | preserve | 895-902 | 895-902 | T48 | control | TREATS | 895 | 902 | preserve | 779-789 | 779-789 | T37 | salmeterol | OrganicChemical | 779 | 789 | preserve | 888-894 | 888-894 | T42 | asthma | DiseaseOrSyndrome | 888 | 894 | A5 | Despite these effects, the short-acting beta-agonist drugs albuterol and terbutaline and the long-acting beta-agonist drugs salmeterol and formoterol have, in general, not been associated with a significant worsening of asthma control or an increased frequency of severe attacks. | 648-947 | 648 | 947 | Despite these effects, the short-acting beta-agonist drugs albuterol and terbutaline and the long-acting beta-agonist drugs @SUBJECT$ and formoterol have, in general, not been associated with a significant worsening of @OBJECT$ @PREDICAT$ or an increased frequency of severe attacks. |
Fact | preserve | 895-902 | 895-902 | T48 | control | TREATS | 895 | 902 | preserve | 728-739 | 728-739 | T33 | terbutaline | OrganicChemical | 728 | 739 | preserve | 888-894 | 888-894 | T42 | asthma | DiseaseOrSyndrome | 888 | 894 | A6 | Despite these effects, the short-acting beta-agonist drugs albuterol and terbutaline and the long-acting beta-agonist drugs salmeterol and formoterol have, in general, not been associated with a significant worsening of asthma control or an increased frequency of severe attacks. | 648-947 | 648 | 947 | Despite these effects, the short-acting beta-agonist drugs albuterol and @SUBJECT$ and the long-acting beta-agonist drugs salmeterol and formoterol have, in general, not been associated with a significant worsening of @OBJECT$ @PREDICAT$ or an increased frequency of severe attacks. |
Fact | preserve | 895-902 | 895-902 | T48 | control | TREATS | 895 | 902 | preserve | 714-723 | 714-723 | T32 | albuterol | OrganicChemical | 714 | 723 | preserve | 888-894 | 888-894 | T42 | asthma | DiseaseOrSyndrome | 888 | 894 | A11 | Despite these effects, the short-acting beta-agonist drugs albuterol and terbutaline and the long-acting beta-agonist drugs salmeterol and formoterol have, in general, not been associated with a significant worsening of asthma control or an increased frequency of severe attacks. | 648-947 | 648 | 947 | Despite these effects, the short-acting beta-agonist drugs @SUBJECT$ and terbutaline and the long-acting beta-agonist drugs salmeterol and formoterol have, in general, not been associated with a significant worsening of @OBJECT$ @PREDICAT$ or an increased frequency of severe attacks. |
Fact | preserve | 1835-1839 | 1835-1839 | T97 | with | PROCESS_OF | 1,835 | 1,839 | preserve | 1880-1903 | 1896-1903 | T95 | coronary artery disease | DiseaseOrSyndrome | 1,880 | 1,903 | preserve | 1826-1834 | 1826-1834 | T92 | patients | PatientOrDisabledGroup | 1,826 | 1,834 | A1 | This article reviews comparative studies between MRI and established imaging techniques like PET, SPECT and dobutamine-echocardiography with respect to the assessment of viable myocardium in patients with acute myocardial infarction and chronic coronary artery disease. | 1617-1904 | 1,617 | 1,904 | This article reviews comparative studies between MRI and established imaging techniques like PET, SPECT and dobutamine-echocardiography with respect to the assessment of viable myocardium in @OBJECT$ @PREDICAT$ acute myocardial infarction and chronic @SUBJECT$ . |
Fact | preserve | 960-974 | 967-974 | T52 | vessel disease | LOCATION_OF | 960 | 974 | preserve | 960-966 | 960-966 | T45 | vessel | BodyPartOrganOrOrganComponent | 960 | 966 | preserve | 967-974 | 967-974 | T46 | disease | DiseaseOrSyndrome | 967 | 974 | A8 | However, due to the complexity of viability assessment especially in patients with severely depressed left ventricular function and multi-vessel disease, viability tests are usually requested after the results of coronary angiography are known. | 810-1072 | 810 | 1,072 | However, due to the complexity of viability assessment especially in patients with severely depressed left ventricular function and multi- @SUBJECT$ @PREDICAT$ @OBJECT$ , viability tests are usually requested after the results of coronary angiography are known. |
Fact | preserve | 140-142 | 140-142 | T24 | in | PROCESS_OF | 140 | 142 | preserve | 104-117 | 104-117 | T7 | dysfunctional | PathologicFunction | 104 | 117 | preserve | 143-151 | 143-151 | T10 | patients | PatientOrDisabledGroup | 143 | 151 | A10 | The identification of dysfunctional but viable myocardium in patients with coronary artery disease with or without a history of myocardial infarction is of paramount clinical importance since viable myocardial areas are most likely to benefit from revascularization, whereas revascularization of scar tissue will not lead to improvement of left ventricular function. | 82-473 | 82 | 473 | The identification of @SUBJECT$ but viable myocardium @PREDICAT$ @OBJECT$ with coronary artery disease with or without a history of myocardial infarction is of paramount clinical importance since viable myocardial areas are most likely to benefit from revascularization, whereas revascularization of scar tissue will not lead to improvement of left ventricular function. |
Fact | preserve | 1593-1595 | 1593-1595 | T79 | in | TREATS | 1,593 | 1,595 | preserve | 1561-1592 | 1579-1592 | T75 | therapeutic interventions | TherapeuticOrPreventiveProcedure | 1,561 | 1,592 | preserve | 1607-1615 | 1607-1615 | T77 | patients | PatientOrDisabledGroup | 1,607 | 1,615 | A11 | With the application of magnetic resonance imaging (MRI) in clinical cardiology an important and exciting diagnostic tool has been added for the prospective identification of viable myocardium for purposes of guiding therapeutic interventions in individual patients. | 1332-1616 | 1,332 | 1,616 | With the application of magnetic resonance imaging (MRI) in clinical cardiology an important and exciting diagnostic tool has been added for the prospective identification of viable myocardium for purposes of guiding @SUBJECT$ @PREDICAT$ individual @OBJECT$ . |
Fact | preserve | 0-14 | 4-14 | T6 | MRI assessment | ISA | 0 | 14 | preserve | 0-3 | 0-3 | T1 | MRI | DiagnosticProcedure | 0 | 3 | preserve | 4-14 | 4-14 | T2 | assessment | HealthCareActivity | 4 | 14 | A12 | MRI assessment of myocardial viability: comparison with other imaging techniques. | 0-81 | 0 | 81 | @SUBJECT$ @PREDICAT$ @OBJECT$ of myocardial viability: comparison with other imaging techniques. |
Fact | preserve | 1835-1839 | 1835-1839 | T97 | with | PROCESS_OF | 1,835 | 1,839 | preserve | 1840-1867 | 1857-1867 | T93 | acute myocardial infarction | DiseaseOrSyndrome | 1,840 | 1,867 | preserve | 1826-1834 | 1826-1834 | T92 | patients | PatientOrDisabledGroup | 1,826 | 1,834 | A13 | This article reviews comparative studies between MRI and established imaging techniques like PET, SPECT and dobutamine-echocardiography with respect to the assessment of viable myocardium in patients with acute myocardial infarction and chronic coronary artery disease. | 1617-1904 | 1,617 | 1,904 | This article reviews comparative studies between MRI and established imaging techniques like PET, SPECT and dobutamine-echocardiography with respect to the assessment of viable myocardium in @OBJECT$ @PREDICAT$ @SUBJECT$ and chronic coronary artery disease. |
Fact | preserve | 152-156 | 152-156 | T25 | with | PROCESS_OF | 152 | 156 | preserve | 163-186 | 179-186 | T11 | coronary artery disease | DiseaseOrSyndrome | 163 | 186 | preserve | 143-151 | 143-151 | T10 | patients | PatientOrDisabledGroup | 143 | 151 | A14 | The identification of dysfunctional but viable myocardium in patients with coronary artery disease with or without a history of myocardial infarction is of paramount clinical importance since viable myocardial areas are most likely to benefit from revascularization, whereas revascularization of scar tissue will not lead to improvement of left ventricular function. | 82-473 | 82 | 473 | The identification of dysfunctional but viable myocardium in @OBJECT$ @PREDICAT$ @SUBJECT$ with or without a history of myocardial infarction is of paramount clinical importance since viable myocardial areas are most likely to benefit from revascularization, whereas revascularization of scar tissue will not lead to improvement of left ventricular function. |
Fact | preserve | 1171-1291 | 1274-1277 | T64 | techniques are single photon emission computed tomography (SPECT), positron emission tomography (PET) if available | ISA | 1,171 | 1,291 | preserve | 1296-1330 | 1307-1330 | T63 | dobutamine stress-echocardiography | DiagnosticProcedure | 1,296 | 1,330 | preserve | 1171-1181 | 1171-1181 | T59 | techniques | FunctionalConcept | 1,171 | 1,181 | A15 | Among the diagnostic armamentarium to identify viable myocardium the most established techniques are single photon emission computed tomography (SPECT), positron emission tomography (PET) if available and dobutamine stress-echocardiography. | 1073-1331 | 1,073 | 1,331 | Among the diagnostic armamentarium to identify viable myocardium the most established @OBJECT$ @PREDICAT$ and @SUBJECT$ . |
Fact | preserve | 782-786 | 782-786 | T37 | with | PROCESS_OF | 782 | 786 | preserve | 787-808 | 801-808 | T36 | single vessel disease | DiseaseOrSyndrome | 787 | 808 | preserve | 774-781 | 774-781 | T35 | patient | PatientOrDisabledGroup | 774 | 781 | A16 | In some patients cardiac catheterization itself already provides important clues to the presence of viable myocardium based on the degree of wall motion abnormalities, post-extrasystolic improvement of wall motion, the presence of collateral vessels or persisting angina in a patient with single vessel disease. | 474-809 | 474 | 809 | In some patients cardiac catheterization itself already provides important clues to the presence of viable myocardium based on the degree of wall motion abnormalities, post-extrasystolic improvement of wall motion, the presence of collateral vessels or persisting angina in a @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Uncommitted | preserve | 343-352 | 343-352 | T28 | interfere | DISRUPTS | 343 | 352 | preserve | 292-303 | 292-303 | T22 | montelukast | OrganicChemical | 292 | 303 | preserve | 368-388 | 382-388 | T26 | anticoagulant effect | OrganOrTissueFunction | 368 | 388 | A2 | This study was designed to evaluate whether montelukast at clinically used dosage levels would interfere with the anticoagulant effect of warfarin. | 242-401 | 242 | 401 | This study was designed to evaluate whether @SUBJECT$ at clinically used dosage levels would @PREDICAT$ with the @OBJECT$ of warfarin. |
Fact | preserve | 581-585 | 581-585 | T46 | with | USES | 581 | 585 | preserve | 571-580 | 571-580 | T41 | treatment | TherapeuticOrPreventiveProcedure | 571 | 580 | preserve | 586-597 | 586-597 | T42 | montelukast | OrganicChemical | 586 | 597 | A3 | In a two-period, double-blind, randomized crossover study, 12 healthy male subjects received a single oral dose of 30 mg warfarin on the 7th day of a 12-day treatment with montelukast, 10 mg daily by mouth, or a placebo. | 402-640 | 402 | 640 | In a two-period, double-blind, randomized crossover study, 12 healthy male subjects received a single oral dose of 30 mg warfarin on the 7th day of a 12-day @SUBJECT$ @PREDICAT$ @OBJECT$ , 10 mg daily by mouth, or a placebo. |
Fact | preserve | 200-209 | 200-209 | T17 | treatment | TREATS | 200 | 209 | preserve | 133-164 | 154-164 | T11 | leukotriene receptor antagonist | OrganicChemical | 133 | 164 | preserve | 213-219 | 213-219 | T13 | asthma | DiseaseOrSyndrome | 213 | 219 | A4 | Montelukast, a cysteinyl leukotriene receptor antagonist, is being developed for the treatment of asthma and related diseases. | 108-241 | 108 | 241 | Montelukast, a cysteinyl @SUBJECT$ , is being developed for the @PREDICAT$ of @OBJECT$ and related diseases. |
Fact | preserve | 108-164 | 154-164 | T19 | Montelukast, a cysteinyl leukotriene receptor antagonist | TREATS | 108 | 164 | preserve | 108-119 | 108-119 | T10 | Montelukast | OrganicChemical | 108 | 119 | preserve | 232-240 | 232-240 | T15 | diseases | DiseaseOrSyndrome | 232 | 240 | A6 | Montelukast, a cysteinyl leukotriene receptor antagonist, is being developed for the treatment of asthma and related diseases. | 108-241 | 108 | 241 | @SUBJECT$ @PREDICAT$ , is being developed for the treatment of asthma and related @OBJECT$ . |
Fact | preserve | 108-164 | 154-164 | T19 | Montelukast, a cysteinyl leukotriene receptor antagonist | TREATS | 108 | 164 | preserve | 108-119 | 108-119 | T10 | Montelukast | OrganicChemical | 108 | 119 | preserve | 213-219 | 213-219 | T13 | asthma | DiseaseOrSyndrome | 213 | 219 | A7 | Montelukast, a cysteinyl leukotriene receptor antagonist, is being developed for the treatment of asthma and related diseases. | 108-241 | 108 | 241 | @SUBJECT$ @PREDICAT$ , is being developed for the treatment of @OBJECT$ and related diseases. |
Fact | preserve | 1249-1252 | 1249-1252 | T79 | for | METHOD_OF | 1,249 | 1,252 | preserve | 1212-1242 | 1237-1242 | T74 | international normalized ratio | LaboratoryProcedure | 1,212 | 1,242 | preserve | 1253-1269 | 1265-1269 | T75 | prothrombin time | LaboratoryProcedure | 1,253 | 1,269 | A9 | Montelukast had no significant effect on the anticoagulant effect of warfarin, as assessed by the international normalized ratio (INR) for prothrombin time (AUC0-144 and INR maximum). | 1102-1303 | 1,102 | 1,303 | Montelukast had no significant effect on the anticoagulant effect of warfarin, as assessed by the @SUBJECT$ (INR) @PREDICAT$ @OBJECT$ (AUC0-144 and INR maximum). |
Fact | preserve | 0-6 | 0-6 | T8 | Effect | INTERACTS_WITH | 0 | 6 | preserve | 70-78 | 70-78 | T5 | warfarin | HazardousOrPoisonousSubstance | 70 | 78 | preserve | 10-21 | 10-21 | T2 | montelukast | OrganicChemical | 10 | 21 | A10 | Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. | 0-107 | 0 | 107 | @PREDICAT$ of @OBJECT$ on the pharmacokinetics and pharmacodynamics of @SUBJECT$ in healthy volunteers. |
Fact | preserve | 108-164 | 154-164 | T16 | Montelukast, a cysteinyl leukotriene receptor antagonist | ISA | 108 | 164 | preserve | 108-119 | 108-119 | T10 | Montelukast | OrganicChemical | 108 | 119 | preserve | 133-164 | 154-164 | T11 | leukotriene receptor antagonist | OrganicChemical | 133 | 164 | A11 | Montelukast, a cysteinyl leukotriene receptor antagonist, is being developed for the treatment of asthma and related diseases. | 108-241 | 108 | 241 | @SUBJECT$ @PREDICAT$ @OBJECT$ , is being developed for the treatment of asthma and related diseases. |
Fact | preserve | 1013-1021 | 1013-1021 | T66 | presence | COEXISTS_WITH | 1,013 | 1,021 | preserve | 983-991 | 983-991 | T64 | warfarin | HazardousOrPoisonousSubstance | 983 | 991 | preserve | 1025-1036 | 1025-1036 | T65 | montelukast | OrganicChemical | 1,025 | 1,036 | A12 | However, slight but statistically significant decreases in time to peak concentration of both warfarin enantiomers and in elimination half-life of the less potent R-warfarin were observed in the presence of montelukast. | 806-1037 | 806 | 1,037 | However, slight but statistically significant decreases in time to peak concentration of both warfarin enantiomers and in elimination half-life of the less potent R- @SUBJECT$ were observed in the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 200-209 | 200-209 | T17 | treatment | TREATS | 200 | 209 | preserve | 133-164 | 154-164 | T11 | leukotriene receptor antagonist | OrganicChemical | 133 | 164 | preserve | 232-240 | 232-240 | T15 | diseases | DiseaseOrSyndrome | 232 | 240 | A13 | Montelukast, a cysteinyl leukotriene receptor antagonist, is being developed for the treatment of asthma and related diseases. | 108-241 | 108 | 241 | Montelukast, a cysteinyl @SUBJECT$ , is being developed for the @PREDICAT$ of asthma and related @OBJECT$ . |
Fact | preserve | 28-30 | 28-30 | T4 | in | TREATS | 28 | 30 | preserve | 15-27 | 15-27 | T2 | intervention | HealthCareActivity | 15 | 27 | preserve | 31-37 | 31-37 | T3 | stroke | DiseaseOrSyndrome | 31 | 37 | A6 | Cost-effective intervention in stroke. | 0-38 | 0 | 38 | Cost-effective @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1051-1058 | 1051-1058 | T64 | prevent | PREVENTS | 1,051 | 1,058 | preserve | 1034-1047 | 1034-1047 | T53 | interventions | HealthCareActivity | 1,034 | 1,047 | preserve | 1059-1065 | 1059-1065 | T54 | stroke | DiseaseOrSyndrome | 1,059 | 1,065 | A7 | This article reviews the epidemiology of stroke (risk factors, incidence, prevalence and the burden of disability and handicap), the various studies dealing with the community and individual costs of stroke, and the cost-effectiveness of interventions to prevent stroke such as control of hypertension, reduction in cigarette intake, encouragement of a healthy lifestyle, antiplatelet or anticoagulant therapy, and carotid endarterectomy. | 778-1246 | 778 | 1,246 | This article reviews the epidemiology of stroke (risk factors, incidence, prevalence and the burden of disability and handicap), the various studies dealing with the community and individual costs of stroke, and the cost-effectiveness of @SUBJECT$ to @PREDICAT$ @OBJECT$ such as control of hypertension, reduction in cigarette intake, encouragement of a healthy lifestyle, antiplatelet or anticoagulant therapy, and carotid endarterectomy. |
Fact | preserve | 315-345 | 333-345 | T32 | bronchial mucosal inflammation | LOCATION_OF | 315 | 345 | preserve | 315-324 | 315-324 | T26 | bronchial | BodyPartOrganOrOrganComponent | 315 | 324 | preserve | 325-345 | 333-345 | T27 | mucosal inflammation | PathologicFunction | 325 | 345 | A3 | The commonest form of asthma is that due to atopy, which is an immune disorder where production of IgE to inhaled antigens leads to bronchial mucosal inflammation. | 171-346 | 171 | 346 | The commonest form of asthma is that due to atopy, which is an immune disorder where production of IgE to inhaled antigens leads to @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1220-1243 | 1234-1243 | T88 | inhaler treatment | ISA | 1,220 | 1,243 | preserve | 1220-1227 | 1220-1227 | T86 | inhaler | MedicalDevice | 1,220 | 1,227 | preserve | 1234-1243 | 1234-1243 | T87 | treatment | TherapeuticOrPreventiveProcedure | 1,234 | 1,243 | A5 | Association with high IgE levels was limited to the interval flanked by D11S1335 and CD20 in a 0.8-Mb interval and was greatest for variants of Fc epsilonRIbeta and HTm4; these variants also associated with asthma (recurrent wheeze with labile airflow obstruction and need for regular inhaler treatment). | 917-1245 | 917 | 1,245 | Association with high IgE levels was limited to the interval flanked by D11S1335 and CD20 in a 0.8-Mb interval and was greatest for variants of Fc epsilonRIbeta and HTm4; these variants also associated with asthma (recurrent wheeze with labile airflow obstruction and need for regular @SUBJECT$ @PREDICAT$ @OBJECT$ ). |
Fact | preserve | 214-220 | 214-217 | T30 | due to | CAUSES | 214 | 220 | preserve | 221-226 | 221-226 | T20 | atopy | PathologicFunction | 221 | 226 | preserve | 193-199 | 193-199 | T19 | asthma | DiseaseOrSyndrome | 193 | 199 | A6 | The commonest form of asthma is that due to atopy, which is an immune disorder where production of IgE to inhaled antigens leads to bronchial mucosal inflammation. | 171-346 | 171 | 346 | The commonest form of @OBJECT$ is that @PREDICAT$ @SUBJECT$ , which is an immune disorder where production of IgE to inhaled antigens leads to bronchial mucosal inflammation. |
Fact | preserve | 221-255 | 221-226 | T29 | atopy, which is an immune disorder | ISA | 221 | 255 | preserve | 221-226 | 221-226 | T20 | atopy | PathologicFunction | 221 | 226 | preserve | 240-255 | 247-255 | T21 | immune disorder | DiseaseOrSyndrome | 240 | 255 | A7 | The commonest form of asthma is that due to atopy, which is an immune disorder where production of IgE to inhaled antigens leads to bronchial mucosal inflammation. | 171-346 | 171 | 346 | The commonest form of asthma is that due to @SUBJECT$ @PREDICAT$ @OBJECT$ where production of IgE to inhaled antigens leads to bronchial mucosal inflammation. |